Showing 4081-4090 of 5623 results for "".
- Study: Bioengineered Cornea Can Restore Sight to the Blind and Visually Impairedhttps://modernod.com/news/study-bioengineered-cornea-can-restore-sight-to-the-blind-and-visually-impaired/2481039/Researchers and entrepreneurs have developed an implant made of collagen protein from pig’s skin, which resembles the human cornea. In a pilot study, the implant restored vision to 20 people with diseased corneas, most of whom were blind prior to receiving the implant, according to Link&oum
- SAV-IOL to Showcase IOL Technology at ESCRS 2022https://modernod.com/news/sav-iol-to-showcase-new-iol-technology-at-escrs-2022/2481038/After nearly 3 years of virtual congresses and canceled tradeshows worldwide, SAV-IOL announced it will be exhibiting at this year’s ESCRS event in Milan, Italy, September 16-19 at stand B14 at MiCo Convention Centre. SAV-IOL invites all participants to come check out their E
- Visibly Becomes First FDA-Cleared Online Vision Test in the United Stateshttps://modernod.com/news/visibly-becomes-first-fda-cleared-online-vision-test-in-the-united-states/2481033/Visibly, the developer of an at-home digital vision testing platform, announced that it has received 510(k) clearance from the FDA for its Visibly Digital Acuity Product (VDAP). Visibly said it is the first FDA-cleared online visual acuity test on the US market. View Eyew
- Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the Omni Surgical System in Patients with Open Angle Glaucomahttps://modernod.com/news/sight-sciences-announces-long-term-safety-and-effectiveness-data-of-standalone-use-of-the-omni-surgical-system-in-patients-with-open-angle-glaucoma/2481030/Sight Sciences announced 36-month post-surgery follow-up results of the Omni Surgical System. The data demonstrate that the OMNI Surgical System delivers safe, consistent, and durable results in adult patients with open-angle glaucoma (OAG) on a standalone basis, according
- Staar Surgical Partners with Joe Jonas to Introduce New EVO ICLhttps://modernod.com/news/staar-surgical-partners-with-joe-jonas-to-introduce-new-evo-icl/2481024/Staar Surgical announced its partnership with singer, songwriter, and actor, Joe Jonas, to raise awareness of its EVO Visian Implantable Collamer Lenses (EVO). EVO is an FDA-approved vision correction lens designed for the correction/reduction of myopia and astigmatism. Mr. Jo
- Clearside Biomedical Enters Into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for Up to $65 Millionhttps://modernod.com/news/clearside-biomedical-enters-into-non-dilutive-financing-agreement-with-healthcare-royalty-partners-for-up-to-65-million/2481020/Clearside Biomedical announced it has entered into an agreement with HealthCare Royalty Partners in a deal worth up to $65 million. Clearside intends to use the proceeds from the agreement to support ongoing clinical development of its pipeline, including CLS-AX (axitini
- Study: Neurolenses Have Significant Impact on Reading Speedhttps://modernod.com/news/neurolenses-have-significant-impact-on-reading-speed/2481017/As has been demonstrated by many studies, contoured prism has historically shown efficacy in relieving symptoms as a therapeutic offering. And new evidence suggests that there is also an opportunity to expand this technology to an even broader population focused on visual performance and producti
- Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Diseasehttps://modernod.com/news/tarsus-initiates-phase-2a-ersa-trial-evaluating-tp-03-for-the-treatment-of-meibomian-gland-disease/2481015/Tarsus Pharmaceuticals announced that it has enrolled the first patient in a phase 2a clinical trial studying TP-03 (lotilaner ophthalmic solution, 0.25%) for the treatment of meibomian gland disease (MGD) in patients with Demodex mites. Demodex
- FDA Approves First Biosimilar Interchangeable to Lucentishttps://modernod.com/news/fda-approves-fyb201cimerli-the-first-and-only-biosimilar-to-lucentis/2481012/Coherus BioSciences announced that the FDA has approved Cimerli (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis (ranibizumab injection) for wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), d
- Pixium Vision Announces Regulatory Approval of Remote Rehabilitation System for Patients in Clinical Trialshttps://modernod.com/news/pixium-vision-announces-regulatory-approval-of-remote-rehabilitation-system-for-patients-in-clinical-trials/2481010/Pixium Vision announced the approval of the remote rehabilitation system for patients enrolled in the PRIMAvera pivotal trial and the French Feasibility Study in atrophic dry age-related macular degeneration (AMD). The approval was granted by the Ethics Commitee and the Regulatory Autho